Evidence map›Paper›PMID 33219461›Full record

ArticleInternational journal of hematology2021

Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience.

Naoko Hosono, Miyuki Ookura, Hiroaki Araie, Mihoko Morita, Kazuhiro Itoh, Yasufumi Matsuda, Takahiro Yamauchi

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Introduction of Carbonyl Groups into Antibodies.Molecules (Basel, Switzerland) · 2023
    Review
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Naoko HosonoDepartment of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Fukui, Matsuoka, 910-1193, Japan. hosono@u-fukui.ac.jp.ORCID http://orcid.org/0000-0002-6336-3250
Miyuki OokuraDepartment of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Fukui, Matsuoka, 910-1193, Japan.
Hiroaki AraieDepartment of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Fukui, Matsuoka, 910-1193, Japan.
Mihoko MoritaDepartment of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Fukui, Matsuoka, 910-1193, Japan.
Kazuhiro ItohDepartment of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Fukui, Matsuoka, 910-1193, Japan.
Yasufumi MatsudaDepartment of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Fukui, Matsuoka, 910-1193, Japan.
Takahiro YamauchiDepartment of Hematology and Oncology, University of Fukui, 23-3, Shimoaizuki, Fukui, Matsuoka, 910-1193, Japan.
University of Fukui · JP

Funding

Japan Society for the Promotion of Science JP 16K09844
6 · The paper itself

Abstract

We retrospectively evaluated the clinical efficacy and toxicity of gemtuzumab ozogamicin (GO) in patients with relapsed acute myeloid leukemia (AML). Nineteen patients (median 70 years) received GO (9 mg/m

Indexed as

Salvage TherapyAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalDrug EvaluationFebrile NeutropeniaFemaleGemtuzumabGenes, Wilms TumorHematoma, SubduralHospitals, UniversityHumansLeukemia, Myeloid, AcuteMaleMiddle AgedAntineoplastic Agents, ImmunologicalGemtuzumabNeoplasm ProteinsWT1 protein, humanWT1 ProteinsAcute myeloid leukemia (AML)Gemtuzumab ozogamicin (GO)RelapsedWilms Tumor 1 (WT1)

Identifiers

PMID33219461
OpenAlexW3099734539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.